Banner
Global Conjugate Vaccine Market Report 2024

Conjugate Vaccine Global Market Report 2024 – By Product Type (Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine), By Pathogen (Bacterial, Viral), By Disease Indication (Pneumococcal, Influenza, Meningococcal, Typhoid), By Patient (Pediatric, Adults), By End-User (Hospitals, Clinics, Homecare Settings, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

Conjugate Vaccine Global Market Report 2024

Starting Price : $5000.00 $4000.00 | Pages : | Published : October 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Conjugate Vaccine Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN

Conjugate Vaccine Market Definition

Conjugate vaccines, also known as immunogen conjugates, are advanced immune system modulators widely employed to develop protection against invading pathogens or make particular antibodies against the target molecule. The conjugation process enhances the immune response and allows for a more effective immune system recognition of the pathogen.

The main types of conjugate vaccines are monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent conjugate vaccines are vaccines that contain a single conjugated antigen, typically targeting a specific pathogen or strain, and are used to prevent infections caused by bacteria that have a polysaccharide capsule, such as streptococcus pneumoniae, haemophilus influenzae type B, and neisseria meningitidis. They are developed with such bacterial and viral pathogens for the treatment of various diseases, including pneumococcal, influenza, meningococcal, and typhoid, for pediatric and adult patients used by hospitals, clinics, homecare settings, and others.

Conjugate Vaccine Market Segmentation

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Global Conjugate Vaccine Market Size 2023 to 2028: Graph

Conjugate Vaccine Market Size 2024 And Growth Rate

The conjugate vaccine market size has grown rapidly in recent years. It will grow from $16.77 billion in 2023 to $19.11 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to disease burden, government immunization programs, increased awareness, pediatric vaccination emphasis, preventive healthcare trends..

Conjugate Vaccine Market Growth Forecast

The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $30.65 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to expanding immunization policies, aging population dynamics, new vaccine indications, global health security concerns, international collaboration, economic development impact. Major trends in the forecast period include collaborations and partnerships for vaccine distribution, tailored approaches for high-risk populations, application in emerging infectious diseases, advancements in vaccine manufacturing technologies, global health initiatives for vaccine equity..

Conjugate Vaccine Market Driver: The Surge In Conjugate Vaccine Use Drives Market Expansion

The increase in the use of conjugate vaccines for adults is expected to propel the growth of the conjugate vaccine market. Conjugate vaccines are designed to stimulate a strong immune response against bacterial capsular polysaccharides, enhancing the body's defense mechanism against bacterial infections. The use of conjugate vaccines in adults helps reduce the risk of severe illness, complications, and transmission of these bacterial diseases by stimulating a robust immune response. For instance, according to the Historical national influenza vaccination coverage 2020-2022, published by the National Centre for Immunization Research and Surveillance, an Australia-based research organization, historical influenza vaccine coverage at the end of 2022 by 15 - < 50 years age group was 29.5%, an increase from 22.8% recorded in 2021. Therefore, the increase in the use of conjugate vaccines for adults is driving the growth of the conjugate vaccine market.

Conjugate Vaccine Market Driver: Rising Infectious Diseases Is Anticipated To Fuel The Growth Of The Conjugate Vaccine Market

The rising incidence of infectious diseases is expected to propel the growth of the conjugate vaccine market. Infectious diseases are disorders caused by pathogenic microorganisms, such as bacteria, viruses, parasites, or fungi, that can be transmitted, directly or indirectly, from one person to another, from animals to humans, or through the environment. Conjugate vaccines play a crucial role in preventing infectious diseases caused by certain bacteria, especially in vulnerable populations such as infants and young children. For instance, in October 2022, according to the Pan American Health Organization, a US-based international health agency, approximately 10.6 million individuals contracted tuberculosis (TB) in 2021, marking a 4.5% rise from 2020. Among those affected, 1.6 million individuals succumbed to TB, including 187,000 cases among people living with HIV. Therefore, the rising incidence of infectious diseases is driving the growth of the conjugate vaccine market.

Global Conjugate Vaccine Market Major Players

Major companies operating in the conjugate vaccine market report are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., AstraZeneca plc, Johnson & Johnson, Moderna Inc., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Inovio Pharmaceuticals Inc., Medicago Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

Global Conjugate Vaccine Market Trend: Navigating The Conjugate Vaccine Market Through Cutting-Edge Solutions

Innovation in conjugate vaccines is a key trend gaining popularity in the conjugate vaccine market. Companies operating in the conjugate vaccine market are focused on developing innovative conjugate vaccines to sustain their position in the market. For instance, in June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, launched Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 includes conjugates for the 13 serotypes already covered by PREVNAR 13 and conjugates for seven additional serotypes associated with invasive pneumococcal disease, high case-fatality rates, antibiotic resistance, and meningitis.

Global Conjugate Vaccine Market Trend: Industry Leader Embraces The Next-Generation 21-Valent Pneumococcal Conjugate Vaccines Advancements

Major companies operating in the conjugate vaccine market are focusing on developing latest conjugate vaccines such as 21-valent pneumococcal conjugate vaccine. The 21-valent pneumococcal conjugate vaccine is a type of vaccine designed to provide protection against infections caused by Streptococcus pneumoniae bacteria. For instance, in April 2022, Merck & Co., Inc., a US-based pharmaceutical company, announced the Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its ‘V116’. The V116 is an 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. V116 is tailor-made to target the strains of pneumococcal bacteria responsible for causing diseases that are most commonly found in adults.

Conjugate Vaccine Market Merger And Acquisition: Gsk Strengthens Vaccine Arm With Affinivax Inc. Acquisition

In August 2022, GSK, a UK-based company engaged in pharmaceutical and biotechnology products, acquired Affinivax Inc. for $2.1 billion. With this acquisition, GSK aims to build a strong portfolio of specialty medicines and vaccines and strengthen its position in advanced pneumococcal vaccines, including AFX3772. Affinivax is a US-based biotechnology company specializing in conjugate vaccine development.

Regional Analysis For The Global Conjugate Vaccine Market

North America was the largest region in the global conjugate vaccine market in 2023. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the conjugate vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The conjugate vaccine market consists of sales of diphtheria, tetanus, and pertussis (DTaP) conjugate vaccine, haemophilus influenza type b (Hib) conjugate vaccine, and E. coli conjugate vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The conjugate vaccine research report is one of a series of new reports from The Business Research Company that provides conjugate vaccine market statistics, including the conjugate vaccine industry's global market size, regional shares, competitors with a conjugate vaccine market share, detailed conjugate vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the conjugate vaccine industry. This conjugate vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Conjugate Vaccine Market Report Forecast And Analysis
Report AttributeDetails
Market Size Value In 2024 $19.11 billion
Revenue Forecast In 2033 $30.65 billion
Growth Rate CAGR of 12.5% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Sanofi S.A.; Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Bharat Biotech International Limited; Serum Institute of India Private Limited; Biological E. Limited; Bavarian Nordic A/S; CSL Limited; Novartis AG; GreenSignal Bio Pharma Limited; Taj Pharmaceuticals Limited; Vaxcyte Inc.; Neuron Biotech Co. Ltd.; Bio-Med Pvt. Ltd.; AstraZeneca plc; Johnson & Johnson; Moderna Inc.; Sinovac Biotech Ltd.; Takeda Pharmaceutical Company Limited; Valneva SE; Dynavax Technologies Corporation; Emergent BioSolutions Inc.; Hualan Biological Engineering Inc.; Inovio Pharmaceuticals Inc.; Medicago Inc.; Mitsubishi Tanabe Pharma Corporation; Panacea Biotec Ltd.; Protein Sciences Corporation; Seqirus
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Conjugate Vaccine Market Characteristics

    3. Conjugate Vaccine Market Trends And Strategies

    4. Conjugate Vaccine Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Conjugate Vaccine Market Size and Growth

    5.1. Global Conjugate Vaccine Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Conjugate Vaccine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Conjugate Vaccine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Conjugate Vaccine Market Segmentation

    6.1. Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Monovalent Conjugate Vaccines

    Multivalent Conjugate Vaccine

    6.2. Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Bacterial

    Viral

    6.3. Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Pneumococcal

    Influenza

    Meningococcal

    Typhoid

    6.4. Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Pediatric

    Adults

    6.5. Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Clinics

    Homecare Settings

    Other End Users

    7. Conjugate Vaccine Market Regional And Country Analysis

    7.1. Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Conjugate Vaccine Market

    8.1. Asia-Pacific Conjugate Vaccine Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Conjugate Vaccine Market

    9.1. China Conjugate Vaccine Market Overview

    9.2. China Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Conjugate Vaccine Market

    10.1. India Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Conjugate Vaccine Market

    11.1. Japan Conjugate Vaccine Market Overview

    11.2. Japan Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Conjugate Vaccine Market

    12.1. Australia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Conjugate Vaccine Market

    13.1. Indonesia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Conjugate Vaccine Market

    14.1. South Korea Conjugate Vaccine Market Overview

    14.2. South Korea Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Conjugate Vaccine Market

    15.1. Western Europe Conjugate Vaccine Market Overview

    15.2. Western Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Conjugate Vaccine Market

    16.1. UK Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Conjugate Vaccine Market

    17.1. Germany Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Conjugate Vaccine Market

    18.5. France Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Conjugate Vaccine Market

    19.9. Italy Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Conjugate Vaccine Market

    20.13. Spain Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Conjugate Vaccine Market

    21.1. Eastern Europe Conjugate Vaccine Market Overview

    21.2. Eastern Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Conjugate Vaccine Market

    22.1. Russia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Conjugate Vaccine Market

    23.1. North America Conjugate Vaccine Market Overview

    23.2. North America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Conjugate Vaccine Market

    24.1. USA Conjugate Vaccine Market Overview

    24.2. USA Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Conjugate Vaccine Market

    25.1. Canada Conjugate Vaccine Market Overview

    25.2. Canada Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Conjugate Vaccine Market

    26.1. South America Conjugate Vaccine Market Overview

    26.2. South America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Conjugate Vaccine Market

    27.1. Brazil Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Conjugate Vaccine Market

    28.1. Middle East Conjugate Vaccine Market Overview

    28.2. Middle East Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Conjugate Vaccine Market

    29.1. Africa Conjugate Vaccine Market Overview

    29.2. Africa Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Conjugate Vaccine Market Competitive Landscape And Company Profiles

    30.1. Conjugate Vaccine Market Competitive Landscape

    30.2. Conjugate Vaccine Market Company Profiles

    30.2.1. Sanofi S.A.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Pfizer Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Merck & Co. Inc.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. GlaxoSmithKline plc

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Bharat Biotech International Limited

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Conjugate Vaccine Market Competitive Benchmarking

    32. Global Conjugate Vaccine Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Conjugate Vaccine Market

    34. Conjugate Vaccine Market Future Outlook and Potential Analysis

    34.1 Conjugate Vaccine Market In 2028 - Countries Offering Most New Opportunities

    34.2 Conjugate Vaccine Market In 2028 - Segments Offering Most New Opportunities

    34.3 Conjugate Vaccine Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: Asia-Pacific, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: Asia-Pacific, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: China, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: China, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: India, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: India, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Japan, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Japan, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Australia, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Australia, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: Indonesia, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: Indonesia, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: South Korea, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: South Korea, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: Western Europe, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: Western Europe, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: UK, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: UK, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: Germany, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: Germany, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: France, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: France, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Italy, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Italy, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Spain, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Spain, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Eastern Europe, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Eastern Europe, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: Russia, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: Russia, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: North America, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: North America, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: USA, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: USA, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: Canada, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: Canada, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: South America, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: South America, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Brazil, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Brazil, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Middle East, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Middle East, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Africa, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 75: Africa, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 76: Sanofi S.A. Financial Performance
  • Table 77: Pfizer Inc. Financial Performance
  • Table 78: Merck & Co. Inc. Financial Performance
  • Table 79: GlaxoSmithKline plc Financial Performance
  • Table 80: Bharat Biotech International Limited Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: Asia-Pacific, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: Asia-Pacific, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: China, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: China, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: India, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: India, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Japan, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Japan, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Australia, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Australia, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: Indonesia, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: Indonesia, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: South Korea, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: South Korea, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: Western Europe, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: Western Europe, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: UK, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: UK, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: Germany, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: Germany, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: France, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: France, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Italy, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Italy, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Spain, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Spain, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Eastern Europe, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Eastern Europe, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: Russia, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: Russia, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: North America, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: North America, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: USA, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: USA, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: Canada, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: Canada, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: South America, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: South America, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Brazil, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Brazil, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Middle East, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Middle East, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Africa, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 75: Africa, Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 76: Sanofi S.A. Financial Performance
  • Figure 77: Pfizer Inc. Financial Performance
  • Figure 78: Merck & Co. Inc. Financial Performance
  • Figure 79: GlaxoSmithKline plc Financial Performance
  • Figure 80: Bharat Biotech International Limited Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the conjugate vaccine market?

Conjugate vaccines, also known as immunogen conjugates, are advanced immune system modulators widely employed to develop protection against invading pathogens or make particular antibodies against the target molecule. The conjugation process enhances the immune response and allows for a more effective immune system recognition of the pathogen. For further insights on the conjugate vaccine market, request a sample here

How will the conjugate vaccine market drivers and restraints affect the conjugate vaccine market dynamics? What forces will shape the conjugate vaccine industry going forward?

The conjugate vaccine market major growth driver - the surge in conjugate vaccine use drives market expansion. For further insights on the conjugate vaccine market, request a sample here

What is the forecast market size or the forecast market value of the conjugate vaccine market ?

The conjugate vaccine market size has grown rapidly in recent years. It will grow from $16.77 billion in 2023 to $19.11 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to disease burden, government immunization programs, increased awareness, pediatric vaccination emphasis, preventive healthcare trends.. The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $30.65 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to expanding immunization policies, aging population dynamics, new vaccine indications, global health security concerns, international collaboration, economic development impact. Major trends in the forecast period include collaborations and partnerships for vaccine distribution, tailored approaches for high-risk populations, application in emerging infectious diseases, advancements in vaccine manufacturing technologies, global health initiatives for vaccine equity.. For further insights on the conjugate vaccine market, request a sample here

How is the conjugate vaccine market segmented?

The conjugate vaccine market is segmented
1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End UsersFor further insights on the conjugate vaccine market,
request a sample here

Which region has the largest share of the conjugate vaccine market? What are the other regions covered in the report?

North America was the largest region in the global conjugate vaccine market in 2023. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the conjugate vaccine market, request a sample here.

Who are the major players in the conjugate vaccine market?

Major companies operating in the conjugate vaccine market report are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., AstraZeneca plc, Johnson & Johnson, Moderna Inc., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Inovio Pharmaceuticals Inc., Medicago Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus For further insights on the conjugate vaccine market, request a sample here.

What are the key trends in the conjugate vaccine market?

Major trend in the conjugate vaccine market - navigating the conjugate vaccine market through cutting-edge solutions. For further insights on the conjugate vaccine market, request a sample here.

What are the major opportunities in the conjugate vaccine market? What are the strategies for the conjugate vaccine market?

For detailed insights on the major opportunities and strategies in the conjugate vaccine market, request a sample here.

How does the conjugate vaccine market relate to the overall economy and other similar markets?

For detailed insights on conjugate vaccine market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the conjugate vaccine industry?

For detailed insights on the mergers and acquisitions in the conjugate vaccine industry, request a sample here.

What are the key dynamics influencing the conjugate vaccine market growth? SWOT analysis of the conjugate vaccine market.

For detailed insights on the key dynamics influencing the conjugate vaccine market growth and SWOT analysis of the conjugate vaccine industry, request a sample here.